A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells-Reference-Cited by-同舟云学术

A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells

Published:2019-01-09 Issue: Volume:9 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Martín-Rodríguez Patricia,Guerra Borja,Hueso-Falcón Idaira,Aranda-Tavío Haidee,Díaz-Chico Juan,Quintana José,Estévez Francisco,Díaz-Chico Bonifacio,Amesty Angel,Estévez-Braun Ana,Fernández-Pérez Leandro

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference58 articles.

1. ERK2, but not ERK1, mediates acquired and “de novo” resistance to imatinib mesylate: implication for CML therapy.;Aceves-Luquero;PLoS One,2009

2. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.;Badache;Cancer Res.,2001

3. Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells.;Bar-Natan;Leukemia,2012

4. In situ screening assay for cell viability using a dimeric cyanine nucleic acid stain.;Becker;Anal. Biochem.,1994

5. Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia.;Berger;Oncotarget,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 1,2,3-Triazole-totarol conjugates as potent PIP5K1α lipid kinase inhibitors;Bioorganic & Medicinal Chemistry;2024-05

2. In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones;Molecules;2023-01-06

3. Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells;BMC Cancer;2022-12-02

4. Hybrid Molecules Containing Naphthoquinone and Quinolinedione Scaffolds as Antineoplastic Agents;Molecules;2022-08-03

5. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia;Biomedicine & Pharmacotherapy;2021-12